IKT Stock — Inhibikase Therapeutics, Inc.: Metrics

Market overview

2 metrics

Share price

$2.50

Market cap

$332.10M

Price action

19 metrics

Price change (1W)

-4.8%

Price change (30D)

+7.7%

Price change (3M)

+40.0%

Price change (6M)

+24.6%

Price change (YTD)

+16.1%

Price change (1Y)

+32.2%

Trailing year

Price change (5Y)

—

52-week high

$2.50

52-week low

$1.41

Change from 52-week high

-4.8%

Change from 52-week low

+68.8%

Annualized volatility

63.7%

Beta

1.5

RSI (14D)

51.9

Price vs SMA 50

+6.7%

Price vs SMA 200

+27.9%

Avg volume (3M)

774,601

Relative volume

0.7

Average dollar volume

$1.61M

Company

3 metrics

Sector

Healthcare

Industry

Biotechnology

Shares outstanding

139.54M

Valuation

12 metrics

P / E (TTM)

—

Trailing earnings

PEG ratio

—

EV / revenue

—

EV / EBITDA

—

EV / EBIT

—

P / sales

—

P / book

2.2

reciprocal yield 46.2%

FCF yield

-12.8%

TTM · current market cap

Buyback yield

—

P / FCF

—

P / operating cash flow

—

Earnings yield

-18.3%

Historical valuation

8 metrics

P / E historical average (3Y)

—

P / E historical average (5Y)

—

EV / revenue historical average (3Y)

18,212,356.5×

reciprocal yield 0.0%

EV / revenue historical average (5Y)

18,212,356.5×

reciprocal yield 0.0%

EV / EBIT historical average (3Y)

—

EV / EBIT historical average (5Y)

—

EV / EBITDA historical average (3Y)

—

EV / EBITDA historical average (5Y)

—

Dividends & buybacks

7 metrics

Dividend yield

—

Trailing 12 months

Payout ratio

—

Shareholder yield

—

Dividend / share (TTM)

—

Dividend growth YoY

—

Dividend growth streak

—

Last ex-dividend

—

Earnings calendar

2 metrics

Next earnings

—

Last earnings

2026-08-11

Profitability

9 metrics

Gross margin

—

Operating margin

—

Trailing 12 months

Net margin

—

Gross profit (TTM)

—

Operating profit (TTM)

−$65.44M

Net income (TTM)

−$60.64M

Trailing 12 months

Diluted EPS (TTM)

$-0.44

FCF margin

—

Effective tax rate

—

Per share

11 metrics

Revenue per diluted share (TTM)

—

Gross profit per diluted share (TTM)

—

Operating profit per diluted share (TTM)

—

EBITDA per diluted share (TTM)

—

Net income per diluted share (TTM)

—

Operating cash flow per diluted share (TTM)

—

Free cash flow per diluted share (TTM)

—

Capital expenditures per diluted share (TTM)

—

R&D per diluted share (TTM)

—

Stock compensation per diluted share (TTM)

—

Book value per share

$5.84

Growth

11 metrics

Revenue growth YoY

-100.0%

Year over year

Net income growth YoY

—

Revenue (TTM)

$0

Trailing 12 months

EPS growth YoY

—

Shares change YoY

+93.9%

Year over year · more shares

Revenue CAGR (3Y)

—

Revenue CAGR (5Y)

—

EPS CAGR (3Y)

—

EPS CAGR (5Y)

—

FCF CAGR (3Y)

—

FCF CAGR (5Y)

—

Quality

14 metrics

Return on equity

-39.5%

Return on assets

-37.1%

Debt / equity

—

Current ratio

15.8

EBITDA (TTM)

—

Free cash flow (TTM)

−$42.61M

Quick ratio

15.8

Interest coverage

—

Net debt / EBITDA

—

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Cash & equivalents

$31.21M

Total assets

$163.59M

Total debt

$381,784

Cash flow & spend

7 metrics

Operating cash flow (TTM)

−$42.61M

Capital expenditures (TTM)

$0

R&D (TTM)

$38.24M

SG&A (TTM)

$27.42M

Stock compensation (TTM)

$19.96M

R&D / revenue

—

Stock compensation / revenue

—

Ownership (13F)

3 metrics

13F filers

106

13F filer change QoQ

+2

Institutional ownership

84.5%

Short interest

3 metrics

Short interest

14.1%

Latest settlement · 35.5 days to cover

Days to cover

35.5d

Short-squeeze score

88 / 100

Insider activity

2 metrics

Net insider buying (90D)

—

Insider-sentiment score

—

Risk flags

1 metrics

Going concern

—

IKT · Inhibikase Therapeutics, Inc.

IKT metrics

Market overview

Price action

Company

Valuation

Historical valuation

Dividends & buybacks

Earnings calendar

Profitability

Growth

Quality

Cash flow & spend

Ownership (13F)

Short interest

Insider activity

Risk flags

No metrics match that search